

# Thomas D Nolin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9259058/publications.pdf>

Version: 2024-02-01

132  
papers

5,544  
citations

61984

43  
h-index

85541

71  
g-index

134  
all docs

134  
docs citations

134  
times ranked

6255  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 305-313.	6.1	323
2	Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimating Equations. <i>American Journal of Kidney Diseases</i> , 2009, 54, 33-42.	1.9	292
3	Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 898-903.	4.7	243
4	Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: Application to studies of oxidative stress. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 554-561.	2.3	202
5	Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest. <i>Clinical Infectious Diseases</i> , 2006, 43, 1603-1611.	5.8	199
6	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	2.2	186
7	Clinical Use of the Urine Biomarker [TIMP-2]∧∧— [IGFBP7] for∧Acute Kidney Injury Risk Assessment. <i>American Journal of Kidney Diseases</i> , 2016, 68, 19-28.	1.9	172
8	Extracorporeal Treatment for Metformin Poisoning. <i>Critical Care Medicine</i> , 2015, 43, 1716-1730.	0.9	162
9	Recommendations for the Role of Extracorporeal Treatments in the Management of Acute Methanol Poisoning. <i>Critical Care Medicine</i> , 2015, 43, 461-472.	0.9	137
10	The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. <i>Journal of the American College of Cardiology</i> , 2013, 62, 505-512.	2.8	128
11	Extracorporeal Treatment for Lithium Poisoning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 875-887.	4.5	128
12	ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2269-2276.	6.1	111
13	Hemodialysis Acutely Improves Hepatic CYP3A4 Metabolic Activity. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2363-2367.	6.1	104
14	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	1.9	103
15	The EXTRIP (<i>EXtracorporeal TReatments In Poisoning</i>) workgroup: Guideline methodology. <i>Clinical Toxicology</i> , 2012, 50, 403-413.	1.9	103
16	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. <i>Annals of Emergency Medicine</i> , 2015, 66, 165-181.	0.6	98
17	Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1533-1539.	4.5	91
18	Bridging Translation by Improving Preclinical Study Design in AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2905-2916.	6.1	90

#	ARTICLE	IF	CITATIONS
19	Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. <i>Clinical Toxicology</i> , 2014, 52, 993-1004.	1.9	85
20	Comparative Evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) Study Equation for Drug Dosing: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , 2011, 31, 1130-1144.	2.6	84
21	Simultaneous analysis of multiple aminothiols in human plasma by high performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3274-3281.	2.3	83
22	Extracorporeal treatment for valproic acid poisoning: Systematic review and recommendations from the EXTRIP workgroup. <i>Clinical Toxicology</i> , 2015, 53, 454-465.	1.9	79
23	Current Understanding of Drug Disposition in Kidney Disease. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 10S-22S.	2.0	73
24	Hemoperfusion for the Treatment of Poisoning: Technology, Determinants of Poison Clearance, and Application in Clinical Practice. <i>Seminars in Dialysis</i> , 2014, 27, 350-361.	1.3	72
25	Mechanisms of Drug-Induced Nephrotoxicity. <i>Handbook of Experimental Pharmacology</i> , 2010, , 111-130.	1.8	71
26	Guidelines for Reporting Case Studies on Extracorporeal Treatments in Poisonings: Methodology. <i>Seminars in Dialysis</i> , 2014, 27, 407-414.	1.3	68
27	Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression. <i>Journal of Pharmacological Sciences</i> , 2008, 108, 157-163.	2.5	66
28	Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 854-867.	4.7	65
29	Altered nonrenal drug clearance in ESRD. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 555-559.	2.0	61
30	Extracorporeal Treatment for Barbiturate Poisoning: Recommendations From the EXTRIP Workgroup. <i>American Journal of Kidney Diseases</i> , 2014, 64, 347-358.	1.9	58
31	Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 719-729.	4.7	55
32	Clopidogrel Efficacy and Cigarette Smoking Status. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2495-6.	7.4	54
33	Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 109, 128-135.	2.8	54
34	Estimation of Kidney Function in Oncology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 587-595.	4.5	54
35	Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 75-87.	4.7	53
36	Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e <sup>-/-</sup> Mice. <i>Scientific Reports</i> , 2018, 8, 14752.	3.3	53

#	ARTICLE	IF	CITATIONS
37	Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 701-709.	1.9	52
38	Use of extracorporeal treatments in the management of poisonings. <i>Kidney International</i> , 2018, 94, 682-688.	5.2	51
39	Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms. <i>American Journal of Kidney Diseases</i> , 2015, 65, 574-582.	1.9	49
40	Extracorporeal treatment for theophylline poisoning: Systematic review and recommendations from the EXTRIP workgroup. <i>Clinical Toxicology</i> , 2015, 53, 215-229.	1.9	49
41	Blood Purification in Toxicology: Nephrology's Ugly Duckling. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 160-166.	1.4	48
42	Pharmacokinetic Assessment in Patients Receiving Continuous RRT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 159-164.	4.5	48
43	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 261-267.	4.5	48
44	Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. <i>Clinical Toxicology</i> , 2016, 54, 103-114.	1.9	46
45	Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 14-20.	1.4	43
46	Extracorporeal Treatment for Tricyclic Antidepressant Poisoning: Recommendations from the EXTRIP Workgroup. <i>Seminars in Dialysis</i> , 2014, 27, 381-389.	1.3	42
47	Extracorporeal Treatment for Thallium Poisoning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1682-1690.	4.5	41
48	Decreased Conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 Following Cholecalciferol Therapy in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1965-1973.	4.5	40
49	Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine. <i>Xenobiotica</i> , 2017, 47, 346-353.	1.1	39
50	Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1025-1039.	0.7	39
51	Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. <i>PLoS ONE</i> , 2017, 12, e0180280.	2.5	39
52	Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup. <i>American Journal of Kidney Diseases</i> , 2016, 67, 187-197.	1.9	33
53	Nonrenal Drug Clearance in CKD: Searching for the Path Less Traveled. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 384-391.	1.4	32
54	Lack of Drug Dosing Guidelines for Critically Ill Patients Receiving Continuous Renal Replacement Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 159-161.	4.7	31

#	ARTICLE	IF	CITATIONS
55	Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. <i>Lancet Oncology</i> , 2021, 22, 1333-1340.	10.7	31
56	A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. <i>Seminars in Dialysis</i> , 2015, 28, 325-329.	1.3	30
57	Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 71-82.	3.1	29
58	Core Competencies for Research Training in the Clinical Pharmaceutical Sciences. <i>American Journal of Pharmaceutical Education</i> , 2011, 75, 27.	2.1	27
59	In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases. <i>Pharmacotherapy</i> , 2014, 34, 114-122.	2.6	26
60	Multiple-Dose Pharmacokinetics and Pharmacodynamics of N-Acetylcysteine in Patients with End-Stage Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1588-1594.	4.5	25
61	Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 618-624.	2.8	24
62	Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico. <i>PLoS ONE</i> , 2016, 11, e0153157.	2.5	23
63	Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1304-1309.	3.3	23
64	Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	22
65	MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. <i>Briefings in Bioinformatics</i> , 2021, 22, 946-962.	6.5	21
66	Drug Transporters and Na <sup>+</sup> /H <sup>+</sup> Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. <i>Pharmacological Reviews</i> , 2015, 67, 656-680.	16.0	17
67	Primary Care of the Renal Transplant Patient. <i>Journal of General Internal Medicine</i> , 2010, 25, 731-740.	2.6	15
68	Impact of Regular or Extended Hemodialysis and Hemodiafiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. <i>Kidney International Reports</i> , 2017, 2, 1050-1058.	0.8	15
69	Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2475-2489.	6.1	15
70	Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy. , 2022, 4, e0688.		15
71	Nocturia and Aging: Diagnosis and Treatment. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, e27-e40.	1.4	14
72	The anti-oxidant effects are not the main mechanism for glutamine's protective effects on acute kidney injury in mice. <i>European Journal of Pharmacology</i> , 2013, 705, 11-19.	3.5	14

#	ARTICLE	IF	CITATIONS
73	Activation of Constitutive Androstane Receptor Ameliorates Renal Ischemia-Reperfusionâ€œInduced Kidney and Liver Injury. <i>Molecular Pharmacology</i> , 2018, 93, 239-250.	2.3	14
74	Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. <i>Critical Care</i> , 2021, 25, 201.	5.8	14
75	Opioids for chronic pain management in patients with dialysis-dependent kidney failure. <i>Nature Reviews Nephrology</i> , 2022, 18, 113-128.	9.6	14
76	Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 506-511.	2.0	13
77	Effect of Experimental Kidney Disease on the Functional Expression of Hepatic Reductases. <i>Drug Metabolism and Disposition</i> , 2015, 43, 100-106.	3.3	13
78	Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2101-2103.	4.5	13
79	Thienopyridine efficacy and cigarette smoking status. <i>American Heart Journal</i> , 2013, 165, 693-703.	2.7	12
80	Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatographyâ€œmass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 265-271.	2.3	11
81	Clinical Relevance of Impaired Nonrenal Drug Clearance in ESRD. <i>Seminars in Dialysis</i> , 2010, 23, 482-485.	1.3	11
82	Determination of warfarin alcohols by ultra-high performance liquid chromatographyâ€œtandem mass spectrometry: Application to in vitro enzyme kinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 944, 63-68.	2.3	11
83	Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease. <i>Scientific Reports</i> , 2019, 9, 15901.	3.3	10
84	Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S36-S51.	2.0	10
85	Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. <i>Kidney360</i> , 2020, 1, 1206-1216.	2.1	10
86	Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 555-568.	4.7	9
87	Adverse Drug Effects in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1075-1077.	4.5	9
88	Kidney function assessment and its role in drug development, review and utilization. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 523-532.	3.1	8
89	Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 241-250.	2.0	8
90	Extracorporeal Treatment for Methotrexate Poisoning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 602-622.	4.5	8

#	ARTICLE	IF	CITATIONS
91	Rapid microtiter plate assay for determination of inulin in human plasma and dialysate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 209-215.	2.8	7
92	Stability of Atropine Sulfate Prepared for Mass Chemical Terrorism. <i>Journal of Toxicology: Clinical Toxicology</i> , 2003, 41, 771-775.	1.5	7
93	Stability of cefepime and metronidazole prepared for simplified administration as a single product. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 179-184.	1.8	7
94	Reply to Chinello and Petrosillo. <i>Clinical Infectious Diseases</i> , 2007, 44, 1389-1391.	5.8	7
95	Implications of Kidney Disease on Metabolic Reduction. <i>Current Drug Metabolism</i> , 2016, 17, 663-672.	1.2	7
96	Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease. <i>Drug Metabolism Letters</i> , 2015, 9, 111-118.	0.8	7
97	Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine. <i>Journal of Chromatographic Science</i> , 2016, 54, 554-560.	1.4	6
98	Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. <i>Kidney International</i> , 2021, 100, 720-736.	5.2	6
99	Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1018-1029.	2.0	6
100	Influence of Smoking on Treatment With Clopidogrel—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1322.	7.4	5
101	A Decade After the KDOQI CKD Guidelines: Impact on Medication Safety. <i>American Journal of Kidney Diseases</i> , 2012, 60, 713-715.	1.9	5
102	Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system. <i>BMC Nephrology</i> , 2014, 15, 204.	1.8	5
103	Estimated GFR and Cystatin C for Drug Dosing: Moving Beyond Proof of Concept to Clinical Translation?. <i>American Journal of Kidney Diseases</i> , 2015, 65, 534-536.	1.9	5
104	Engaging and Empowering Stakeholders to Advance Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 305-308.	4.7	5
105	In Reply to “Estimated GFR for Drug Dosing: A Bedside Formula”, “Drug Dose Adjustments in Patients With Renal Impairment”, “Use of the MDRD Study Equation for Drug Dosing”, and “Estimated GFR vs Creatinine Clearance for Drug Dosing”. <i>American Journal of Kidney Diseases</i> , 2009, 54, 985-986.	1.9	4
106	Optimizing Drug Development and Use in Patients With Kidney Disease: Opportunities, Innovations, and Challenges. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 4S-6S.	2.0	4
107	Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. <i>Pharmacotherapy</i> , 2021, 41, 463-478.	2.6	4
108	Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of <sup>14</sup> C <sub>2</sub> Production Rate Data. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 151-161.	2.5	3

#	ARTICLE	IF	CITATIONS
109	Drug Metabolism in Chronic Kidney Disease. , 2020, , 1035-1051.		3
110	On Warfarin Use in Kidney Disease: A Therapeutic Window of Opportunity?. American Journal of Kidney Diseases, 2010, 56, 805-808.	1.9	2
111	Optimizing Drug Development and Use in Patients With Kidney Disease. Journal of Clinical Pharmacology, 2011, 51, 628-630.	2.0	2
112	What is the Role of Renal Replacement Therapy in the Setting of Dabigatran Toxicity?. Seminars in Dialysis, 2014, 27, 223-226.	1.3	2
113	Introduction to Nephro pharmacology for the Clinician. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1083-1084.	4.5	2
114	Assessing the effect of extracorporeal treatments for lithium poisoning. British Journal of Clinical Pharmacology, 2021, 87, 214-215.	2.4	2
115	Physiologically Based Pharmacokinetic Modeling of Vitamin D <sub>3</sub> and Metabolites in Vitamin D-Insufficient Patients. Drug Metabolism and Disposition, 2022, 50, 1161-1169.	3.3	2
116	Application of a map Bayesian method for CYP2E1 phenotyping. Clinical Pharmacology and Therapeutics, 2004, 75, P41.	4.7	1
117	A New Forum for Brief Research Reports in AJKD. American Journal of Kidney Diseases, 2010, 55, 975-976.	1.9	1
118	TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX Study. Journal of the American College of Cardiology, 2012, 60, B17.	2.8	1
119	Extracorporeal treatment in salicylate poisoning. Clinical Toxicology, 2019, 57, 377-378.	1.9	1
120	Hemodialysis removal of caffeine. American Journal of Emergency Medicine, 2020, 38, 1273-1274.	1.6	1
121	Application of Individualized PBPK Modeling of Rate Data to Evaluate the Effect of Hemodialysis on Nonrenal Clearance Pathways. Journal of Clinical Pharmacology, 2021, 61, 769-781.	2.0	1
122	New Vancomycin Dosing Guidelines for Hemodialysis Patients: Rationale, Caveats, and Limitations. Kidney360, 2021, 2, 1313-1315.	2.1	1
123	Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy. American Journal of Kidney Diseases, 2021, 78, 151-153.	1.9	1
124	Principles of Drug Therapy in Patients with Reduced Kidney Function. , 2014, , 337-345.		0
125	Drugs, Dialysis, Decisions, and Data: A Walk through the Minefield of Nephro pharmacology. Seminars in Dialysis, 2015, 28, 323-324.	1.3	0
126	Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia. Xenobiotica, 2021, 51, 1-11.	1.1	0

#	ARTICLE	IF	CITATIONS
127	Drug dosing in kidney disease. , 2012, , 57-68.		0
128	627. Critical Care Medicine, 2014, 42, A1511.	0.9	0
129	Hemoglobin Inhibits Uptake of Filtered Proteins by Proximal Tubule Cells: Implications for Sickle Cell Disease and Vitamin D Status. FASEB Journal, 2018, 32, 849.13.	0.5	0
130	Pharmacokinetics in patients requiring renal replacement therapy. , 2022, , 73-90.		0
131	Effect of kidney disease on pharmacokinetics. , 2022, , 61-72.		0
132	The Impact of Suboptimal 25-hydroxyvitamin D Levels and Cholecalciferol Replacement on the Pharmacokinetics of Oral Midazolam in Control Subjects and Patients with Chronic Kidney Disease. Journal of Clinical Pharmacology, 0, , .	2.0	0